Essentiality of FASII pathway for Staphylococcus aureus

Arising from: S. Brinster et al. 458, 83–86 (2009)10.1038/nature07772; Brinster et al. replyRecently, Brinster et al. suggested that type II fatty-acid biosynthesis (FASII) is not a suitable antibacterial target for Gram-positive pathogens because they use fatty acids directly from host serum rather than de novo synthesis. Their findings, if confirmed, are relevant for further scientific and financial investments in the development of new drugs targeting FASII. We present here in vitro and in vivo data demonstrating that their observations do not hold for Staphylococcus aureus, a major Gram-positive pathogen causing several human infections. The observed differences among Gram-positive pathogens in FASII reflects heterogeneity either in fatty-acid synthesis or in the capacity for fatty-acid uptake from the environment.

[1]  C. Rock,et al.  Mechanistic diversity and regulation of Type II fatty acid synthesis. , 2002, Biochemical Society transactions.

[2]  B. Finlay,et al.  Exploitation of mammalian host cell functions by bacterial pathogens. , 1997, Science.

[3]  B. Staels,et al.  Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens , 2009, Nature.

[4]  R. Altenbern,et al.  Cerulenin-Inhibited Cells of Staphylococcus aureus Resume Growth When Supplemented with Either a Saturated or an Unsaturated Fatty Acid , 1977, Antimicrobial Agents and Chemotherapy.

[5]  R. Heath,et al.  Fatty acid biosynthesis as a target for novel antibacterials. , 2004, Current opinion in investigational drugs.

[6]  Chang Ki Kim,et al.  In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea , 2007, Antimicrobial Agents and Chemotherapy.

[7]  Michael Otto,et al.  Staphylococcus aureus Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor Mprf Is Based on Modification of Membrane Lipids with l-Lysine , 2001, The Journal of experimental medicine.

[8]  D. de Mendoza,et al.  Isolation and Characterization of Unsaturated Fatty Acid Auxotrophs of Streptococcus pneumoniae and Streptococcus mutans , 2007, Journal of bacteriology.

[9]  Jun Wang,et al.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.

[10]  Yinduo Ji,et al.  Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. , 2004, FEMS microbiology letters.

[11]  A. Ullrich,et al.  Interplay between mycobacteria and host signalling pathways , 2004, Nature Reviews Microbiology.

[12]  C. Rock,et al.  Membrane lipid homeostasis in bacteria , 2008, Nature Reviews Microbiology.

[13]  C. Vilchèze,et al.  Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid , 2006, Nature Medicine.

[14]  R J Heath,et al.  Lipid biosynthesis as a target for antibacterial agents. , 2001, Progress in lipid research.

[15]  C. Weidenmaier,et al.  DltABCD- and MprF-Mediated Cell Envelope Modifications of Staphylococcus aureus Confer Resistance to Platelet Microbicidal Proteins and Contribute to Virulence in a Rabbit Endocarditis Model , 2005, Infection and Immunity.

[16]  Martha S. Head,et al.  Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.